4-Hydroxybenzylamine, also known as p-hydroxybenzylamine, is a naturally occurring compound found in various plants. It is a precursor to the neurotransmitter dopamine and is involved in the biosynthesis of the catecholamines, a group of neurotransmitters that regulate mood, attention, and other brain functions. The compound has been shown to exhibit various pharmacological activities, including antidepressant, anti-inflammatory, and antioxidant effects. Research has focused on exploring its potential therapeutic applications in conditions such as Parkinson's disease, depression, and Alzheimer's disease. 4-Hydroxybenzylamine is typically synthesized through chemical reactions, but it is also produced naturally by certain plants, such as coffee beans and tea leaves. Its biological importance lies in its role as a precursor to dopamine, and its potential as a therapeutic agent for various diseases.'
```
4-hydroxybenzylamine: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 97472 |
| CHEMBL ID | 202519 |
| CHEBI ID | 173335 |
| SCHEMBL ID | 63123 |
| MeSH ID | M0140274 |
| Synonym |
|---|
| AC-16618 |
| 4-aminomethyl-phenol |
| BB 0240833 |
| CHEBI:173335 |
| nsc-125720 |
| nsc125720 |
| 696-60-6 |
| 4-hydroxybenzylamine |
| 4-(aminomethyl)phenol |
| STK502926 |
| CHEMBL202519 , |
| bdbm50177412 |
| AKOS000131573 |
| (4-hydroxyphenyl)methylammonium bromide |
| A836589 |
| (4-hydroxyphenyl)methanaminium bromide |
| 7j7f85b7bi , |
| nsc 125720 |
| para-hydroxybenzylamine |
| phenol, 4-(aminomethyl)- |
| unii-7j7f85b7bi |
| FT-0632832 |
| PS-5924 |
| AM20060931 |
| BP-21023 |
| SCHEMBL63123 |
| p-(aminomethyl)pheno |
| 4-hydroxybenzenemethanamine |
| (4-hydroxyphenyl)methanamine |
| ((4-hydroxyphenyl)methyl)amine |
| p-hydroxybenzenemethanamine |
| p-cresol, .alpha.-amino- |
| p-hydroxybenzylamine |
| 4-hydroxybenzyl amine |
| 4-hydroxylbenzylamine |
| 4-(amino methyl)phenol |
| 4-hydroxy benzylamine |
| 4-hyroxybenzylamine |
| RQJDUEKERVZLLU-UHFFFAOYSA-N |
| 4-aminomethylphenol |
| DTXSID00219872 |
| J-513629 |
| mfcd00870499 |
| 4-(aminomethyl)-phenol |
| 4-(aminomethyl)phenol, 9ci |
| a-amino-p-cresol |
| CS-W004078 |
| tetrahydro-2h-pyran-4-ylacetylchloride |
| 4 hydroxy amino toluene |
| EN300-44825 |
| SB38361 |
| Q27268396 |
| 4-hydroxybenzylamine, min. 98% by hplc |
| 4-hoba |
| HY-W004078 |
| CK2396 |
| SY002006 |
| PD096512 |
| Class | Description |
|---|---|
| aromatic amine | An amino compound in which the amino group is linked directly to an aromatic system. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Cytokinin dehydrogenase 1 | Zea mays | Km | 5.5000 | 1.8000 | 3.6500 | 5.5000 | AID416147 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| mitochondrion | Succinate-semialdehyde dehydrogenase, mitochondrial | Homo sapiens (human) |
| mitochondrial matrix | Succinate-semialdehyde dehydrogenase, mitochondrial | Homo sapiens (human) |
| synapse | Succinate-semialdehyde dehydrogenase, mitochondrial | Homo sapiens (human) |
| mitochondrion | Succinate-semialdehyde dehydrogenase, mitochondrial | Homo sapiens (human) |
| mitochondrion | 4-aminobutyrate aminotransferase, mitochondrial | Homo sapiens (human) |
| mitochondrial matrix | 4-aminobutyrate aminotransferase, mitochondrial | Homo sapiens (human) |
| 4-aminobutyrate transaminase complex | 4-aminobutyrate aminotransferase, mitochondrial | Homo sapiens (human) |
| mitochondrion | 4-aminobutyrate aminotransferase, mitochondrial | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1574519 | Cytotoxicity against human MCF7 cells assessed as decrease in cell viability treated every 24 hrs measured after 72 hrs by alamar blue assay | 2019 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 29, Issue:2 | Diarylcarbonates are a new class of deubiquitinating enzyme inhibitor. |
| AID416147 | Activity at Zea mays CKX1 expressed in Pichinia pastoris assessed as aldehyde production by 4-aminophenol assay | 2009 | Bioorganic & medicinal chemistry, Mar-01, Volume: 17, Issue:5 | Synthesis, characterization and biological activity of ring-substituted 6-benzylamino-9-tetrahydropyran-2-yl and 9-tetrahydrofuran-2-ylpurine derivatives. |
| AID260086 | Inhibitory activity against GABAT | 2006 | Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3 | Inhibition of GABA shunt enzymes' activity by 4-hydroxybenzaldehyde derivatives. |
| AID416148 | Ratio Kcat to Km for Zea mays CKX1 receptor | 2009 | Bioorganic & medicinal chemistry, Mar-01, Volume: 17, Issue:5 | Synthesis, characterization and biological activity of ring-substituted 6-benzylamino-9-tetrahydropyran-2-yl and 9-tetrahydrofuran-2-ylpurine derivatives. |
| AID260087 | Inhibitory activity against SSADH | 2006 | Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3 | Inhibition of GABA shunt enzymes' activity by 4-hydroxybenzaldehyde derivatives. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (26.05) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||